Arcus Biosciences Advances Casdatifan Phase 3 Trials
Arcus Biosciences Inc. shares rose by 7.92% as the stock reached a 20-day high amid broader market declines.
The company is advancing its PEAK-1 Phase 3 trial for casdatifan, aiming to establish it as the standard of care for clear cell renal cell carcinoma. Arcus plans to present updated progression-free survival data from the ARC-20 study at a medical conference in February 2026, alongside its financial stability with approximately $1 billion in cash to support operations until at least 2028.
This advancement in clinical trials and the financial backing positions Arcus favorably in the competitive landscape of oncology, potentially attracting more investor interest as they continue to develop innovative treatments.
Trade with 70% Backtested Accuracy
Analyst Views on RCUS
About RCUS
About the author
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
- Clinical Trial Advancement: Arcus is executing its ongoing PEAK-1 Phase 3 trial to establish casdatifan as the standard of care for clear cell renal cell carcinoma, with a goal of rapid patient enrollment to complete the study within 18 months.
- Data Presentation Plans: At least three data presentations for casdatifan are anticipated in 2026, including updated progression-free survival (PFS) data from the ARC-20 study involving 121 patients, to be showcased at a medical conference in February 2026.
- Financial Stability: With approximately $1 billion in cash and investments, Arcus expects to fund its operations until at least the second half of 2028, ensuring the continuity of its development plans.
- New Drug Development: Arcus aims to advance its first small molecule MRGPRX2 antagonist into clinical development in 2026, targeting chronic spontaneous urticaria, highlighting the company's strategic focus in the inflammation and immunology sector.
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
- Share Sale: Arcus Biosciences President Juan C. Jaen sold 82,997 shares through indirect holdings for $2,050,598, representing 5.91% of total holdings, indicating a larger-than-usual disposition compared to historical trades.
- Holding Changes: Post-transaction, Jaen retains 367,220 shares directly while indirect holdings drop to 954,063 shares, reflecting a significant decrease in indirect ownership and changes in internal liquidity.
- Market Reaction: The sale occurred near the stock's one-year high, and shortly after, the company announced a clinical trial failure, leading to a 14% drop in stock price in a single day, highlighting market uncertainty about the company's future.
- Financial Position: Despite challenges, Arcus maintains approximately $1 billion in cash and has promising early results for its kidney cancer candidate, with critical data expected throughout 2026, potentially offering opportunities for investors.
Arcus Biosciences Insider Sells 82,997 Shares for $2.1 Million Amid Market Highs
- Insider Sale: On December 4, 2025, Arcus Biosciences President Juan C. Jaen sold 82,997 shares through an indirect holding for approximately $2.1 million, reducing his total holdings by 5.91%, indicating potential concerns about the company's future prospects.
- Market Reaction: This transaction occurred just before the company announced the discontinuation of its STAR-221 trial on December 12 due to futility, which triggered a 14% single-day drop in stock price, highlighting the market's sensitivity to the company's outlook.
- Financial Position: Despite the clinical setback, Arcus maintains a robust balance sheet with around $1 billion in cash, and its kidney cancer candidate casdatifan has shown promising early-stage results, with critical late-stage data expected throughout 2026, potentially supporting future growth.
- Investment Risks: As a clinical-stage biotech firm, Arcus carries significant market volatility, with single trial results capable of causing dramatic price swings, making it a potential opportunity for risk-tolerant investors at current levels.
Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication
Discontinuation of STAR-221 Study: Arcus Biosciences has halted the Phase 3 STAR-221 study in collaboration with Gilead Sciences due to futility, as the combination treatment did not show improved overall survival compared to the standard therapy.
Impact on Stock Performance: Following the announcement, Arcus Biosciences' stock (RCUS) fell by 11.10%, reflecting investor concerns over the study's results and future prospects.
Focus on Casdatifan: Arcus will shift its research and development efforts towards casdatifan, a promising HIF-2α inhibitor, which has shown strong efficacy in late-line clear cell renal cell carcinoma patients.
Advancements in Oncology and I&I Pipelines: The company is also progressing with quemliclustat for pancreatic cancer and plans to introduce new oral small-molecule candidates targeting inflammatory conditions by 2026.
Significant Options Trading on Friday: SEI, CAVA, RCUS
CAVA Options Activity: CAVA Group Inc (CAVA) has seen a trading volume of 21,313 options contracts today, equating to about 2.1 million underlying shares, which is 51.5% of its average daily trading volume over the past month.
High Volume Call Option for CAVA: The $55 strike call option expiring on December 12, 2025, has particularly high activity, with 4,275 contracts traded, representing approximately 427,500 underlying shares.
RCUS Options Activity: Arcus Biosciences Inc (RCUS) has recorded a volume of 9,160 options contracts today, representing around 916,000 underlying shares, or 51.3% of its average daily trading volume over the past month.
High Volume Call Option for RCUS: The $15 strike call option expiring on April 17, 2026, has seen significant trading, with 5,417 contracts exchanged, corresponding to about 541,700 underlying shares.
Arcus Biosciences Grants Stock Options to Employees
- Stock Option Grant: Arcus Biosciences granted stock options totaling 16,650 shares to three new employees at an exercise price of $22.13 per share, reflecting the company's commitment to talent retention and motivation.
- Restricted Stock Units: The company also awarded 8,400 shares in restricted stock units, aimed at enhancing employee loyalty and long-term incentives, thereby promoting overall company growth.
- Inducement Plan Context: These equity awards were granted under the company's 2020 Inducement Plan, which was approved by the Board in January 2020, aligning with the NYSE's
Arcus Advances Casdatifan Phase 3 Trials, Plans Three Data Presentations in 2026
- Clinical Trial Advancement: Arcus is executing its ongoing PEAK-1 Phase 3 trial to establish casdatifan as the standard of care for clear cell renal cell carcinoma, with a goal of rapid patient enrollment to complete the study within 18 months.
- Data Presentation Plans: At least three data presentations for casdatifan are anticipated in 2026, including updated progression-free survival (PFS) data from the ARC-20 study involving 121 patients, to be showcased at a medical conference in February 2026.
- Financial Stability: With approximately $1 billion in cash and investments, Arcus expects to fund its operations until at least the second half of 2028, ensuring the continuity of its development plans.
- New Drug Development: Arcus aims to advance its first small molecule MRGPRX2 antagonist into clinical development in 2026, targeting chronic spontaneous urticaria, highlighting the company's strategic focus in the inflammation and immunology sector.
Arcus Biosciences President Sells 82,997 Shares for Over $2.05 Million
- Share Sale: Arcus Biosciences President Juan C. Jaen sold 82,997 shares through indirect holdings for $2,050,598, representing 5.91% of total holdings, indicating a larger-than-usual disposition compared to historical trades.
- Holding Changes: Post-transaction, Jaen retains 367,220 shares directly while indirect holdings drop to 954,063 shares, reflecting a significant decrease in indirect ownership and changes in internal liquidity.
- Market Reaction: The sale occurred near the stock's one-year high, and shortly after, the company announced a clinical trial failure, leading to a 14% drop in stock price in a single day, highlighting market uncertainty about the company's future.
- Financial Position: Despite challenges, Arcus maintains approximately $1 billion in cash and has promising early results for its kidney cancer candidate, with critical data expected throughout 2026, potentially offering opportunities for investors.
Arcus Biosciences Insider Sells 82,997 Shares for $2.1 Million Amid Market Highs
- Insider Sale: On December 4, 2025, Arcus Biosciences President Juan C. Jaen sold 82,997 shares through an indirect holding for approximately $2.1 million, reducing his total holdings by 5.91%, indicating potential concerns about the company's future prospects.
- Market Reaction: This transaction occurred just before the company announced the discontinuation of its STAR-221 trial on December 12 due to futility, which triggered a 14% single-day drop in stock price, highlighting the market's sensitivity to the company's outlook.
- Financial Position: Despite the clinical setback, Arcus maintains a robust balance sheet with around $1 billion in cash, and its kidney cancer candidate casdatifan has shown promising early-stage results, with critical late-stage data expected throughout 2026, potentially supporting future growth.
- Investment Risks: As a clinical-stage biotech firm, Arcus carries significant market volatility, with single trial results capable of causing dramatic price swings, making it a potential opportunity for risk-tolerant investors at current levels.
Arcus Overhauls Cancer Development Strategy After Trial Setback, Focuses on Kidney Medication
Discontinuation of STAR-221 Study: Arcus Biosciences has halted the Phase 3 STAR-221 study in collaboration with Gilead Sciences due to futility, as the combination treatment did not show improved overall survival compared to the standard therapy.
Impact on Stock Performance: Following the announcement, Arcus Biosciences' stock (RCUS) fell by 11.10%, reflecting investor concerns over the study's results and future prospects.
Focus on Casdatifan: Arcus will shift its research and development efforts towards casdatifan, a promising HIF-2α inhibitor, which has shown strong efficacy in late-line clear cell renal cell carcinoma patients.
Advancements in Oncology and I&I Pipelines: The company is also progressing with quemliclustat for pancreatic cancer and plans to introduce new oral small-molecule candidates targeting inflammatory conditions by 2026.
Significant Options Trading on Friday: SEI, CAVA, RCUS
CAVA Options Activity: CAVA Group Inc (CAVA) has seen a trading volume of 21,313 options contracts today, equating to about 2.1 million underlying shares, which is 51.5% of its average daily trading volume over the past month.
High Volume Call Option for CAVA: The $55 strike call option expiring on December 12, 2025, has particularly high activity, with 4,275 contracts traded, representing approximately 427,500 underlying shares.
RCUS Options Activity: Arcus Biosciences Inc (RCUS) has recorded a volume of 9,160 options contracts today, representing around 916,000 underlying shares, or 51.3% of its average daily trading volume over the past month.
High Volume Call Option for RCUS: The $15 strike call option expiring on April 17, 2026, has seen significant trading, with 5,417 contracts exchanged, corresponding to about 541,700 underlying shares.
